Blood-Filtering therapy may tame rare brain inflammation in children
NCT ID NCT03274375
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This trial investigates whether a blood-filtering procedure called immunoadsorption (IA), combined with the drug rituximab, can improve neurological function in children aged 0-18 with severe anti-NMDAR encephalitis. Participants receive 10 IA sessions over 28 days plus weekly rituximab for four weeks. The study measures changes in disability scores to see if the treatment helps reduce brain inflammation and improve outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
immunoadsorption therapy (IA) and rituximab
What this could lead to
If successful, this approach could offer a more effective way to control severe anti-NMDAR encephalitis in children, potentially reducing long-term disability.
What could go wrong
This is a small Phase 2 study with only 20 participants, so results may not apply broadly. The treatment involves risks from both immunoadsorption and rituximab, including infection and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-NMDAR ENCEPHALITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Necker Enfants-Malades
Paris, Paris, 75015, France